{
    "id": 18292,
    "fullName": "MSLN wild-type",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "Wild-type MSLN indicates that no mutation has been detected within the MSLN gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 10232,
        "geneSymbol": "MSLN",
        "terms": [
            "MSLN",
            "MPF",
            "SMRP"
        ]
    },
    "variant": "wild-type",
    "createDate": "02/19/2016",
    "updateDate": "01/08/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4460,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, 60% (12/20) of evaluable pleural mesothelioma patients experienced a partial response and 15% (3/20) had stable disease when treated with SS1P (PMID: 24989332).",
            "molecularProfile": {
                "id": 18630,
                "profileName": "MSLN wild-type"
            },
            "therapy": {
                "id": 3520,
                "therapyName": "SS1P",
                "synonyms": null
            },
            "indication": {
                "id": 7474,
                "name": "malignant pleural mesothelioma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4560,
                    "pubMedId": 24989332,
                    "title": "Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24989332"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4443,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, heavily pre-treated patients with metastatic pancreatic ductal adenocarcinoma treated with CRS-207 and GVAX (n=61) had an improved overall survival (6.1 months vs 3.9 months) relative to patients in the placebo arm (n=29) (PMID: 25584002).",
            "molecularProfile": {
                "id": 18630,
                "profileName": "MSLN wild-type"
            },
            "therapy": {
                "id": 3512,
                "therapyName": "CRS-207 + GVAX pancreatic cancer vaccine",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4550,
                    "pubMedId": 25584002,
                    "title": "Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25584002"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4444,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, patients with pleural mesothelioma treated with amatuximab had an objective response rate of 91% (40% (n=33) partial response, 51% (n=42) stable disease) and a median overall survival of 14.8 months (PMID: 25231400).",
            "molecularProfile": {
                "id": 18630,
                "profileName": "MSLN wild-type"
            },
            "therapy": {
                "id": 3513,
                "therapyName": "Amatuximab",
                "synonyms": null
            },
            "indication": {
                "id": 7474,
                "name": "malignant pleural mesothelioma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4552,
                    "pubMedId": 25231400,
                    "title": "Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25231400"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4459,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, 55% (11/20) of evaluable patients wtih mesothelioma, colorectal cancer, and ovarian cancer had a partial response to amatuximab (PMID: 21037025).",
            "molecularProfile": {
                "id": 18630,
                "profileName": "MSLN wild-type"
            },
            "therapy": {
                "id": 3513,
                "therapyName": "Amatuximab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4558,
                    "pubMedId": 21037025,
                    "title": "Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21037025"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 18630,
            "profileName": "MSLN wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}